Skip to content
Screener

Kura Oncology KURA Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Amgen logo
AmgenAMGN
$574M+5.9%
Exelixis logo
ExelixisEXEL
$281.45M+71.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$130.89M-15.0%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$40.1M+702%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M—
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$849.57M+76.7%
Enterprise value$834.76M+99.5%
P/S11.9×+3.3×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219481
Line itemMarch 31, 2026December 31,2025
(Unaudited)
Assets
Current assets
Cash and cash equivalents$39,083$149,099
Short-term investments541,740518,141
Accounts receivable, net9,3488,804
Inventory843413
Prepaid expenses and other current assets32,76832,206

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Kura Oncology's cash & equivalents?
Kura Oncology (KURA) reported cash & equivalents of $39.08M in Q1 2026.
How has Kura Oncology's cash & equivalents changed year-over-year?
Kura Oncology's cash & equivalents decreased by 23.8% year-over-year, from $51.27M to $39.08M.
What is the long-term trend for Kura Oncology's cash & equivalents?
Over 5 years (2020 to 2025), Kura Oncology's cash & equivalents has grown at a -14.5% compound annual growth rate (CAGR), from $325.49M to $149.1M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Kura Oncology's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude